In Brief: Biocontrol Technology
This article was originally published in The Gray Sheet
Executive Summary
Biocontrol Technology: Wholly owned subsidiary IDT in conjunction with HemoCleanse initiates expanded Phase II studies of its whole-body extracorporeal hyperthermia (WBHT) utilizing the BioLogic-HT System for treatment of HIV/AIDS. Biocontrol is conducting the studies at St. Elizabeth Hospital Medical Center in Lafayette, Indiana. The treatment involves "artificially inducing a fever by heating the blood to affect the HIV which is known to be heat sensitive." The expanded Phase II trials will commence with enrollment of 60 new patients after treatment of the control group from Biocontrol's 1995 Phase II study. New patients will be randomized and patients in the treatment group will receive two treatments at 42C four days apart. The second treatment will include two hours of therapy time, compared to only one in the 1995 trial. The companies hope the change will lead to "a more significant kill of HIV-infected cells"...